Bridge BioResearch Announces the Granting of US Patent for CD14
26-Jan-2012
- United Kingdom
Originally acquired from the Spanish Biotech company Mellitus, BBR has continued research in animal models verifying pharmacological properties of the CD14 molecule. BBR has now achieved the granting of the US patent, which according to Mr. Soren Stenderup, CEO of BBR, further strengthens the IP position of CD14 as this complements the already issued European patent.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.